Related Experiment Video
Updated: Jul 2, 2025

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
A multiparametric risk table for loss of clinical remission status in patients with rheumatoid arthritis: a
Simone Perniola1,2, Stefano Alivernini1,3,4, Elisa Gremese1,2,4
1Immunology Research Core Facility, Gemelli Science and Technology Park (GSTeP) - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Objective:
This post-hoc analysis was carried out on data acquired in the longitudinal Sonographic Tenosynovitis Assessment in RheumaToid arthritis patiEnts in Remission (STARTER) study. Our primary aim was to determine the predictive clinical and musculoskeletal ultrasonographic (MSUS) features associated with disease flare in RA patients in clinical remission, while our secondary aim was to evaluate the probability of disease flare based on clinical and MSUS features.
Methods:
We analysed data for a total of 389 RA patients in DAS28-defined remission. All patients underwent a MSUS examination according to the OMERACT guidelines. Logistic regression and results, presented as odds ratio and 95% CI, were used for the evaluation of the association between selected variables and disease flare. Significant clinical and MSUS features were incorporated into a risk table for predicting disease flare within at least 12 months of follow-up in patients with RA remission.
Results:
Within 12 months, 137 (35%) RA patients experienced a disease flare. RA patients who experienced a flare disease differed from those with persistent remission in terms of ACPA positivity (75.9% vs 62.3%, respectively; P = 0.007), percentage of sustained clinical remission at baseline (44.1% vs 68.5%, respectively; P = 0.001) and synovium power Doppler signal presence (58.4% vs 33.3%, respectively; P < 0.001). Based on these results, these three features were considered in a predictive model of disease flare with an adjusted odds ratio of 3.064 (95% CI 1.728-5.432). Finally, a risk table was constructed including the three significant predictive factors of disease flare occurring within 12 months from the enrolment.
Conclusion:
An adaptive flare-prediction model tool, based on data available in outpatient settings, was developed as a multiparametric risk table. If confirmed by external validation, this tool might support the defining of therapeutic strategies in RA patients in DAS28-defined remission status.
Related Concept Videos
Hazard Ratio
For example, in a clinical trial...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Relative Risk
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Receiver Operating Characteristic Plot
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

